0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint | Health Care Reform

The Colchicine Debacle

B. Joseph Guglielmo, PharmD
JAMA Intern Med. 2013;173(3):184-185. doi:10.1001/jamainternmed.2013.1405.
Text Size: A A A
Published online

Extract

In 1763, Baron von Storck demonstrated that colchicum extract was useful in the treatment of gout. Some 50 years later, an alkaloid was identified from the autumn crocus (Colchicum autumnale), which ultimately resulted in the discovery of colchicine. While used in the United States for decades, colchicine, similar to other older drugs, had never been approved with respect to efficacy and safety. The Food, Drug, and Cosmetics Act of 19381 and its 1962 amendments (Kefauver Harris Amendments) charged the US Food and Drug Administration (FDA) with approving medications based on safety and efficacy. Drugs that entered the market before the passage of the 1938 act or the 1962 amendments to the act, including colchicine, are often referred to as grandfathered drugs. Under the 1962 grandfather clause, a drug was exempted from the effectiveness requirements if its composition and labeling had not changed since 1962 and if it was sold commercially in the United States. While many older drugs without FDA approval claim to be grandfathered, very few marketed drugs are truly entitled to grandfather status because most differ from the previous versions in some respect, such as formulation, dosage or strength, or dosage form. The 1938 act and the 1962 amendments require the FDA to review and approve medications already being marketed; colchicine is one such unapproved product, which has been awaiting FDA approval since 1938.

Topics

colchicine

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Cochicine's other indications
Posted on February 12, 2013
Joerg Wiesenfeldt
Verbundkrankenhaus Bernkastel-Wittlich, Germany
Conflict of Interest: None Declared

My 2010 BNF copy discloses two other uses of low dose colchicine: familial mediterranean fever (unlicensd) and prevention of gout when starting patients on allopurinol. Why should those indications be affected by the FDA approval for "Colcrys" ?

Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();